Skip to main content
main-content
Erschienen in: Die Diabetologie 4/2022

20.05.2022 | Fettleber | DDG Praxisempfehlungen

Diabetes und Fettleber

verfasst von: Prof. Dr. med. Norbert Stefan, Prof. Dr. Dr. h. c. med. univ. Michael Roden

Erschienen in: Die Diabetologie | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft ( https://​www.​deutsche-diabetes-gesellschaft.​de/​behandlung/​leitlinien) befinden sich alle PDF zum kostenlosen Download. …
Literatur
1.
Zurück zum Zitat Younossi ZM, Koenig AB, Abdelatif D et al (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84 CrossRef Younossi ZM, Koenig AB, Abdelatif D et al (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:73–84 CrossRef
2.
Zurück zum Zitat Younossi ZM (2019) Non-alcoholic fatty liver disease—A global public health perspective. J Hepatol 70:531–544 CrossRef Younossi ZM (2019) Non-alcoholic fatty liver disease—A global public health perspective. J Hepatol 70:531–544 CrossRef
3.
Zurück zum Zitat Eigentler T, Lomberg D, Machann J et al (2020) Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade. Ann Intern Med 172:836–837 CrossRef Eigentler T, Lomberg D, Machann J et al (2020) Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade. Ann Intern Med 172:836–837 CrossRef
4.
Zurück zum Zitat Estes C, Anstee QM, Arias-Loste MT et al (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 69:896–904 CrossRef Estes C, Anstee QM, Arias-Loste MT et al (2018) Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol 69:896–904 CrossRef
5.
Zurück zum Zitat Stefan N, Häring HU, Cusi K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7:313–324 CrossRef Stefan N, Häring HU, Cusi K (2019) Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 7:313–324 CrossRef
6.
Zurück zum Zitat Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5‑year follow-up study. Lancet Diabetes Endocrinol 7:684–694 CrossRef Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5‑year follow-up study. Lancet Diabetes Endocrinol 7:684–694 CrossRef
7.
Zurück zum Zitat Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14:32–42 CrossRef Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14:32–42 CrossRef
8.
Zurück zum Zitat European Association for the Study of the Liver (EASL), European European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:1121–1140 CrossRef European Association for the Study of the Liver (EASL), European European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2016) EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59:1121–1140 CrossRef
9.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357 CrossRef Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357 CrossRef
10.
Zurück zum Zitat Bril F, McPhaul MJ, Caulfield MP et al (2019) Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 67:303–311 CrossRef Bril F, McPhaul MJ, Caulfield MP et al (2019) Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med 67:303–311 CrossRef
11.
Zurück zum Zitat Singh S, Allen AM, Wang Z et al (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643–654.e1–9 CrossRef Singh S, Allen AM, Wang Z et al (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and metaanalysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643–654.e1–9 CrossRef
12.
Zurück zum Zitat Adams LA, Anstee QM, Tilg H et al (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153 CrossRef Adams LA, Anstee QM, Tilg H et al (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153 CrossRef
Metadaten
Titel
Diabetes und Fettleber
verfasst von
Prof. Dr. med. Norbert Stefan
Prof. Dr. Dr. h. c. med. univ. Michael Roden
Publikationsdatum
20.05.2022
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 4/2022
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-022-00906-4

Weitere Artikel der Ausgabe 4/2022

Die Diabetologie 4/2022 Zur Ausgabe

Einführung zum Thema

Diabetes im Krankenhaus

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft basieren überwiegend auf den evidenzbasierten Leitlinien und den evidenzbasierten nationalen Versorgungsleitlinien der DDG und werden jährlich dem Stand der Wissenschaft angepasst.